Hydrochloric Acid

Hydrochloric Acid

SCHEMBL160732

Cl.NCC(O)C1CCCCCCC1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO

The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
SLC6A2 known ✓ P23975 1/20 0.40
SLC6A4 known ✓ P31645 1/20 0.40
SLC6A3 known ✓ Q01959 1/20 0.40
KDM4E B2RXH2 2/20 1.00
GMNN O75496 1/20 1.00
LMNA P02545 1/20 1.00
MAPT P10636 1/20 1.00
BLM P54132 1/20 1.00
PMP22 Q01453 1/20 1.00
SMN1; SMN2 Q16637 1/20 1.00
TP53 P04637 1/20 0.95
EPHX1 P07099 2/20 0.54
ALDH1A1 P00352 1/20 0.45
SHBG P04278 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL2063394 1.00 KDM4E (1.00) KDM4EGMNNLMNAMAPTBLM
SCHEMBL5228082 0.97 TP53 (1.00) KDM4EGMNNLMNAMAPTBLM
Hydrochloric Acid SCHEMBL30187467 0.97 KDM4E (0.95) KDM4EGMNNLMNAMAPTBLM
Hydrochloric Acid SCHEMBL19642704 0.97 KDM4E (0.95) KDM4EGMNNLMNAMAPTBLM
SCHEMBL4079339 0.97 TP53 (1.00) KDM4EGMNNLMNAMAPTBLM
SCHEMBL23270700 0.97 TP53 (1.00) KDM4EGMNNLMNAMAPTBLM
SCHEMBL133228 0.97 TP53 (1.00) KDM4EGMNNLMNAMAPTBLM
SCHEMBL4078170 0.97 TP53 (1.00) KDM4EGMNNLMNAMAPTBLM
SCHEMBL3647508 0.95
SCHEMBL22535894 0.95

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 438 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023059810-A1 STENTS AND METHODS OF USE UNIVERSITY OF CONNECTICUT (US) 2023-04-13 WO claimed
WO-2023044463-A1 SILK FIBROIN DERIVED BRUSH-LIKE POLYMERS UNIVERSITY OF CONNECTICUT (US) 2023-03-23 WO claimed
EP-3129065-B1 TARGETED DRUG DELIVERY THROUGH AFFINITY BASED LINKERS AKAMARA THERAPEUTICS INC (US) 2026-05-13 EP disclosed
EP-4734896-A2 BIOPOLYMER-BASED TYMPANOSTOMY TUBES WITH PROGRAMMABLE, TUNABLE, AND ON-DEMAND DEGRADATION Trustees Of Tufts College (US) 2026-05-06 EP disclosed
EP-4735018-A2 CENTRIFUGALLY-MOLDED ARTICLES AND METHODS Trustees Of Tufts College (US) 2026-05-06 EP disclosed
US-20250332090-A1 TOPICAL FORMULATION COMPRISING OMEGA-3 FATTY ACIDS, MELATONIN AND VITAMIN D AMBO INNOVATIONS LLC (US) 2025-10-30 US disclosed
WO-2025227091-A1 IMPROVED WHIPPED SILK CREAMS AND METHODS OF MAKING AND USING THE SAME TRUSTEES OF TUFTS COLLEGE (US) 2025-10-30 WO disclosed
US-20250136770-A1 SILK FIBROIN DERIVED BRUSH-LIKE POLYMERS NATIONAL SCIENCE FOUNDATION 2025-05-01 US disclosed
WO-2025091012-A1 IMPROVED SILK LEATHER AND METHODS OF MAKING AND USING THE SAME TRUSTEES OF TUFTS COLLEGE (US) 2025-05-01 WO disclosed
EP-4522126-A1 TOPICAL FORMULATION COMPRISING OMEGA-3 FATTY ACIDS, MELATONIN AND VITAMIN D Ambo Innovation LLC (US) 2025-03-19 EP disclosed
WO-2025054426-A1 EDIBLE TRANSFERABLE HOLOGRAPHIC IMAGE FILMS AND METHODS TRUSTEES OF TUFTS COLLEGE (US) 2025-03-13 WO disclosed
US-5674521-A DRUG DELIVERY SYSTEM COMPRISING POLYMER GEL NETWORK INCLUDING BIOLOGICALLY ACTIVE SOLUTE, SALT, LOADING POLYMER; REDUCED LOSS OF ACTIVITY UNIVERSITY OF CINCINNATI (US) 1997-10-07 US disclosed
US-5603955-A GEL NETWORK; PROTECTIVE POLYMER; PROTECTANT SALT UNIVERSITY OF CINCINNATI (US) 1997-02-18 US disclosed
WO-1997000275-A2 RESPONSIVE POLYMER NETWORKS AND METHODS OF THEIR USE GEL SCIENCES, INC. (US) 1997-01-03 WO disclosed
WO-1996002276-A2 NOVEL POLYMER GEL NETWORKS AND METHODS OF USE GEL SCIENCES, INC. (US) 1996-02-01 WO disclosed
US-5409710-A Foam cell drug delivery ENDOCON, INC. (US) 1995-04-25 US disclosed
WO-1994023706-A1 FOAM CELL DRUG DELIVERY ENDOCON, INC. (US) 1994-10-27 WO disclosed
EP-0584220-A1 ENGINEERING THE LOCAL INFLAMMATORY RESPONSE AS A MEANS OF CONTROLLED RELEASE DRUG DELIVERY ENDOCON, INC. (US) 1994-03-02 EP disclosed
WO-1993023012-A1 LIQUID-CONTAINING DRUG DELIVERY SYSTEM ENDOCON, INC. (US) 1993-11-25 WO disclosed
WO-1992020325-A1 ENGINEERING THE LOCAL INFLAMMATORY RESPONSE AS A MEANS OF CONTROLLED RELEASE DRUG DELIVERY ENDOCON, INC. (US) 1992-11-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250136770-A1 SILK FIBROIN DERIVED BRUSH-LIKE POLYMERS NAPA, BST2, SIGLEC7 SLC6A2 4121/4885SLC6A4 4289/4885SLC6A3 3584/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.